TECH Stock Forecast: Bio-Techne Corp. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Bio-Techne Corp. hold a median 12-month price target of $73 — +0.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 96 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Bio-Techne Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (92): The share price has been relatively steady.
Growth (69): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TECH stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TECH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Wells Fargo | Downgrade | Equal-Weight | $62 → $73 |
| 9 July 2026 | RBC Capital | Downgrade | Sector Perform | $62 → $73 |
| 30 June 2026 | Benchmark | Downgrade | Hold | — |
| 30 June 2026 | TD Cowen | Downgrade | Hold | — |
| 29 June 2026 | Citigroup | Downgrade | Neutral | — |
| 26 June 2026 | Baird | Maintains | Neutral | — |
| 26 June 2026 | Stephens & Co. | Downgrade | Equal-Weight | — |
| 26 June 2026 | William Blair | Downgrade | Market Perform | — |
| 11 June 2026 | Piper Sandler | Initiates | Neutral | — |
| 15 May 2026 | RBC Capital | Reinstates | Outperform | $62 |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 7 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 6 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 6 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 5 Feb 2026 | Citigroup | Maintains | Buy | — |
| 5 Feb 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 5 Feb 2026 | Stifel | Maintains | Hold | — |
| 5 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 5 Feb 2026 | UBS | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TECH.
This page is one stock. Monday covers all of them.
TECH appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TECH vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Bio-Techne Corp. returned +24.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TECH analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 66.7×
- Price / sales
- 9.3×
- Price / book
- 5.3×
- EV / EBITDA
- 34.9×
Cheaper than 12% of US stocks
Cheaper than 12% of US stocks
Cheaper than 17% of US stocks
Cheaper than 9% of US stocks
- Revenue growth (YoY)
- 4.6%
- Earnings growth (YoY)
- −25.9%
- Gross margin
- 65.8%
- Operating margin
- 21.7%
- Net margin
- 14.0%
Higher than 39% of US stocks
Higher than 18% of US stocks
Higher than 79% of US stocks
Higher than 81% of US stocks
Higher than 75% of US stocks
- Return on equity
- 8.3%
- Return on assets
- 6.5%
- Dividend yield
- 0.4%
Higher than 58% of US stocks
Higher than 82% of US stocks
Higher than 7% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bio-Techne Corp. has a market value of $11.4B and an enterprise value of $11.4B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 1.3% year on year.
Net income over the same four quarters: $181.9M, a 15.0% net margin.
Diluted earnings per share, trailing twelve months: $1.15.
Free cash flow in the twelve months to 30 June 2026: $263.2M.
Bio-Techne Corp. spent $41.7M on share buybacks and $49.9M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 66.7×; forward P/E: 31.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.44%, paying out 29% of earnings.
Bio-Techne Corp. employs 3,000 people — $405K of revenue per employee.
Data provided by Twelve Data
TECH and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TECH’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Bio-Techne Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TECH
What is the TECH stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Bio-Techne Corp. have a median 12-month price target of $73, with estimates ranging from $50 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TECH stock a buy right now?
Of the 13 analysts covering Bio-Techne Corp., 0 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bio-Techne Corp. 96 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TECH?
As at 21 Nov 2026, Bio-Techne Corp. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).
Will TECH stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +0.4% from the last close, and Ticker Nerd's factor model ranks Bio-Techne Corp. 96 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TECH stock forecast for 2030?
No analyst covering Bio-Techne Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TECH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $73 over the next 12 months.
How has TECH stock performed over the past year?
Bio-Techne Corp. returned +24.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bio-Techne Corp. do?
Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings.
About Bio-Techne Corp.
Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings. The company’s products include proteins, antibodies, immunoassays, ELISA kits, molecular diagnostics, spatial biology tools, and specialized instruments used to detect, measure, and analyze biological activity. Bio-Techne also provides custom services such as antibody development, protein degradation solutions, gene engineering, and cell and gene therapy-related services. Through its Protein Sciences and Diagnostics and Spatial Biology businesses, Bio-Techne plays an important role in enabling scientific discovery, biomarker analysis, and laboratory testing across the global healthcare and life sciences market.
CEO Mr. Kim Kelderman · 3,000 employees · United States · https://www.bio-techne.com